Subclinical hypothyroidism,lipid metabolism and cardiovascular disease |
| |
| Institution: | 1. Clinica Medica, Azienda Ospedaliero Universitaria di Sassari, Viale San Pietro 8, 07100, Sassari, Italy;2. Department of Clinical and Experimental Medicine, University of Sassari – Azienda Ospedaliero Universitaria di Sassari, Viale San Pietro 8, 07100 Sassari, Italy;3. Center for developmental biology and reprogramming - CEDEBIOR, Department of Biomedical Sciences, University of Sassari, Viale San Pietro 43/B, 07100 Sassari, Italy;4. Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche (CNR), Monserrato, Cagliari, Italy;5. National Institute of Biostructures and Biosystems at the Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola - Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy;1. Endocrinology and Diabetes, Salford Royal NHS Foundation Trust and University Teaching Hospital, Salford, Greater Manchester, UK;2. Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, the University of Manchester, Manchester, UK;3. Gastroenterology, Salford Royal NHS Foundation Trust and University Teaching Hospital, Salford, Greater Manchester, UK;4. Manchester Medical School, Faculty of Medical and Human Sciences, the University of Manchester, Manchester, UK;1. Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark;2. Department of Clinical Institute, Aalborg University, Denmark;3. Department of Endocrinology, Bispebjerg University Hospital, Copenhagen, Denmark;4. Centre for Clinical Research and Prevention, Capital Region of Denmark, Copenhagen, Denmark;5. Department of Internal Medicine, Slagelse Hospital, Slagelse, Denmark |
| |
| Abstract: | Subclinical hypothyroidism is defined by elevated serum thyrotropin in presence of normal free thyroid hormones. Lipid metabolism is influenced by thyroid hormone and many reports showed that lipids status worsen along with TSH level. Subclinical hypothyroidism has been also linked to other cardiovascular risk factors such as alteration in blood pressure and increased atherosclerosis. Further evidences suggested that mild dysfunction of thyroid gland is associated with metabolic syndrome and heart failure. Thyrotropin level seems the best predictor of cardiovascular disease, in particular when its levels are above 10 mU/L. However, despite these observations, there is no clear evidence that levothyroxine therapy in subjects with milder form of subclinical hypothyroidism could improve lipid status and the other cardiovascular risk factors. In this review, we address the effect of thyroid hormone and cardiovascular risk, with a focus on lipid metabolism. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
